评估滤泡性淋巴瘤一线临床试验入组标准的影响:MER/LEO队列分析
该研究比较了196例单中心滤泡性淋巴瘤(FL)患者与10项临床试验的入组标准,并分析了24项一线FL方案入组标准对MER和LEO前瞻性队列中1198例II-IV期FL患者的影响。结果显示,基于clinicaltrials.gov和方案文件的标准可能分别排除39.8%和52.7%的患者;放宽分期和血小板要求可扩大入组人群且不影响结局。
要点
- 基于clinicaltrials.gov和方案文件的标准可能分别排除39.8%和52.7%的FL患者。
- 因肾功能、既往恶性肿瘤和自报严重健康问题被排除的患者 tended to be older。
- 将分期要求从III-IV期放宽至II-IV期,MER和LEO队列可入组人群分别增加21%和8%,不影响人口学特征或结局。
核心结论
- 数据提示,老年FL患者的管理可能未充分参考近期临床试验。
- 放宽分期和血小板标准可能扩大合格人群并加快试验入组,且不影响结局。
研究设计与样本
- 比较196例来自单中心的FL患者特征与clinicaltrials.gov上10项一线FL试验的入组标准。
- 汇总24项一线FL方案的入组标准,评估其对前瞻性分子流行病学资源(MER)和淋巴瘤流行病学结局(LEO)队列研究中1198例II至IV期FL患者的影响。
主要发现
- 基于clinicaltrials.gov和方案文件的标准,可能分别排除39.8%和52.7%的FL患者。
- 因肾功能、既往恶性肿瘤和自报严重健康问题被排除的患者 tended to be older。
- 将分期要求从III-IV期扩大至II-IV期,MER队列人群增加21%,LEO队列增加16%,不影响患者人口学特征或结局。
- 将血小板要求从≥150 000扩大至≥75 000,MER队列人群增加8%,LEO队列增加13%,不影响患者人口学特征或结局。
关键数值与推荐
- 基于clinicaltrials.gov标准,39.8%的FL患者可能被排除。
- 基于方案文件标准,52.7%的FL患者可能被排除。
- 分期从III-IV期扩大至II-IV期:MER人群增加21%,LEO人群增加16%。
- 血小板从≥150 000扩大至≥75 000:MER人群增加8%,LEO人群增加13%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer clinical trial eligibility criteria may create patient populations studied in trials that do not reflect the patient populations treated in the real-world setting. Follicular lymphoma (FL) is an indolent lymphoma with heterogeneous presentations across a broad range of individuals, resulting in many acceptable management strategies. We evaluated how first-line clinical trial eligibility criteria impacted the demographic makeup and outcomes of patients with FL for whom systemic therapy might be considered. We compared the characteristics of 196 patients with FL from a single institution to eligibility criteria from 10 first-line FL trials on clinicaltrials.gov. Next, we tabulated eligibility criteria from 24 first-line FL protocols and evaluated their impact on 1198 patients with FL with stages II to IV disease from the prospective Molecular Epidemiology Resource (MER) and Lymphoma Epidemiology of Outcomes (LEO) cohort studies. We found that 39.8% and 52.7% of patients with FL might be excluded from clinical trials based on eligibility criteria derived from clinicaltrials.gov and protocol documents, respectively. Patients excluded because of renal function, prior malignancy, and self-reported serious health conditions tended to be older. Expanding stage requirement from III-IV to II-IV, and platelet requirement from ≥150 000 to ≥75 000 increased population size by 21% and 8%, respectively, in MER and by 16% and 13%, respectively, in LEO, without impacting patient demographics or outcomes. These data suggest that management of older individuals with FL may not be fully informed by recent clinical trials. Moreover, liberalizing stage and platelet criteria might expand the eligible population and allow for quicker trial accrual without impacting outcomes.
引用
- Luan D, Fatola T, Toure A, et al. Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis. Blood Adv. 2022. PMID: 35793440. doi:10.1182/bloodadvances.2022007687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。